Light-triggered OVA release based on CuS@poly(lactide-co-glycolide acid) nanoparticles for synergistic photothermal-immunotherapy of tumor

Chen, Zhenzhen; Zhang, Qian; Zeng, Liang; Zhang, Jialiang; Liu, Zhihong; Zhang, Minxin; Zhang, Xueting; Xu, Hang; Hong-tao, Song; Tao, Chun

doi:10.1016/j.phrs.2020.104902

Cited by 19 publications

(14 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The contents of TGF-β1 and IL-1β were obtained according to the OD value and the standard curve. 20 , 25–27 …”

Section: Methodsmentioning

confidence: 99%

“…[16][17][18][19] For transmission electron microscopy (TEM) characterization, the CNP solution was applied to a 200-mesh copper net and then dried at room temperature prior to TEM detection (JEM-1400, JEOL, Japan). [19][20][21]…”

Section: Characterization Of the Cnpsmentioning

confidence: 99%

“…The contents of TGF-β1 and IL-1β were obtained according to the OD value and the standard curve. 20,[25][26][27] SOD and CAT Assays of the CNPs BC cells were cultured in 6-well plates. After adherence, the culture medium was aspirated, and 2.5 mL of DMEM medium (containing NP carrier concentration of 1, 2, 4 or 8 mg/mL) was added and co-incubated with the cells.…”

Section: Immunocompatibility Test Of the Cnpsmentioning

confidence: 99%

See 2 more Smart Citations

Preparation, Biocompatibility and Antitumor Activity of Nanodelivery System Targeting Breast Cancer Base on a Silica Nanoparticle

Liu¹,

Ren²,

Zhang³

et al. 2021

OTT

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common type of cancer among women worldwide, and about 30% of males will have recurrent disease. Methods: In order to treat recurrent BC, we designed a type of silica nanodelivery system loaded with epirubicin and curcumin (composite nanoparticles, CNPs). To promote CNPs clinical application, the stability, the blood, immune and cell compatibility, skin stimulation experiments, anti-tumor activity in vivo and in vitro were studied. Results: In our study, the CNPs had a particle size of 73.9 nm and a uniform size and morphology; moreover, they maintained physical and chemical stability in the blood protein environment. Additionally, results showed that nanoparticles had good blood and immune compatibility, and they did not affect intracellular superoxide dismutase (SOD) and intracellular catalase (CAT). Skin stimulation experiments showed that CNPs did not cause any obvious irritative damage to the intact skin of rabbits. In the cytotoxicity study, CNPs showed strongest antitumor activity. The results of cell cycle and apoptosis studies showed that CNPs could mainly induce apoptosis of S and G2/M phase cells. In vivo, CNPs showed strongest aggregation in the tumor after 6 h of tail vein administration, and a large amount of CNPs continued to accumulate in the blood after 12 h of administration, indicating that CNPs had long circulation ability. The in vivo antitumor activities showed that CNPs had the strongest antitumor activity and tumor targeting ability, and hematoxylin-eosin staining of internal organs showed no obvious difference between treatment groups and negative control. Conclusion:CNPs have an ideal biosafety and therapeutic effect for recurrent BC, and they have potential clinical application value.

show abstract

“…The contents of TGF-β1 and IL-1β were obtained according to the OD value and the standard curve. 20 , 25–27 …”

Section: Methodsmentioning

confidence: 99%

Section: Characterization Of the Cnpsmentioning

confidence: 99%

Section: Immunocompatibility Test Of the Cnpsmentioning

confidence: 99%

See 1 more Smart Citation

Preparation, Biocompatibility and Antitumor Activity of Nanodelivery System Targeting Breast Cancer Base on a Silica Nanoparticle

Liu¹,

Ren²,

Zhang³

et al. 2021

OTT

View full text Add to dashboard Cite

show abstract

“…Recently, a combination therapy that delivers drug molecules and adjuvants has achieved rapid establishment of anti-tumor immunity in tumors [138]. For example, it induces the infiltration of circulating cancer-specific T cells, stimulates the maturation of cytotoxic T cells, down-regulates regulatory T cells and promotes the secretion of inflammatory factors [139,140]. Therapies based on immune checkpoints have also made progress in relieving T cell suppression and changing the tumor microenvironment [112,141].…”

Section: T Cellsmentioning

confidence: 99%

“…In addition, DC, as the most powerful antigen-presenting cell, also has a good absorption capacity for micro/nanoparticles. Presenting antigens by direct or crossover methods promotes the activation of T lymphocytes and produces a cellular immune response dominated by CD8+T cell infiltration, which is the basis of DC as an immunotherapy method [126,140]. However, the immunosuppression in the tumor microenvironment leads to a decrease in the number of DCs and their function is inhibited [156].…”

Section: Dendritic Cellsmentioning

confidence: 99%

PLGA-based drug delivery system for combined therapy of cancer: research progress

et al. 2021

Mater. Res. Express

View full text Add to dashboard Cite

In recent years, PLGA micro/nano particle drug delivery systems has been widely used in cancer treatment. According to the unique properties of PLGA, carriers of various structures are designed to keep the function of drugs or bioactive substances, ensure the effective load of molecules and improve the bioavailability of drugs in diseased parts. PLGA is one of the earliest and most commonly used biodegradable materials. It is often used for functional modification with other polymers (such as polyethylene glycol and chitosan) or other molecules (such as aptamers and ligands) to deliver various small molecule drugs (such as DOX and DTX) and bioactive macromolecules (such as proteins and nucleic acids) to improve targeting, controlled release and therapeutic properties. In this paper, the preparation methods, physical and chemical properties and medical applications of PLGA micro/nano particles are discussed. We focused on the recent research progress of the PLGA-based drug carrier system in tumor combination therapy.

show abstract

Multifunctional inorganic nanomaterials for cancer photoimmunotherapy

Tang

Zhang

et al. 2022

Cancer Communications

View full text Add to dashboard Cite

Phototherapy and immunotherapy in combination is regarded as the ideal therapeutic modality to treat both primary and metastatic tumors. Immunotherapy uses different immunological approaches to stimulate the immune system to identify tumor cells for targeted elimination. Phototherapy destroys the primary tumors by light irradiation, which induces a series of immune responses through triggering immunogenic cancer cell death. Therefore, when integrating immunotherapy with phototherapy, a novel anti-cancer strategy called photoimmunotherapy (PIT) is emerging. This synergistic treatment modality can not only enhance the effectiveness of both therapies but also overcome their inherent limitations, opening a new era for the current anti-cancer therapy. Recently, the advancement of nanomaterials affords a platform for PIT. From all these nanomaterials, inorganic nanomaterials stand out as ideal mediators in PIT due to their unique physiochemical properties. Inorganic nanomaterials can not only serve as carriers to transport immunomodulatory agents in immunotherapy owing to their excellent drug-loading capacity but also function as photothermal agents or photosensitizers in phototherapy because of their great optical characteristics. In this review, the recent advances of multifunctional inorganic nanomaterial-mediated drug delivery and their contributions to cancer PIT will be highlighted.

show abstract

Light-triggered OVA release based on CuS@poly(lactide-co-glycolide acid) nanoparticles for synergistic photothermal-immunotherapy of tumor

Cited by 19 publications

References 39 publications

Preparation, Biocompatibility and Antitumor Activity of Nanodelivery System Targeting Breast Cancer Base on a Silica Nanoparticle

Preparation, Biocompatibility and Antitumor Activity of Nanodelivery System Targeting Breast Cancer Base on a Silica Nanoparticle

PLGA-based drug delivery system for combined therapy of cancer: research progress

Multifunctional inorganic nanomaterials for cancer photoimmunotherapy

Contact Info

Product

Resources

About